Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04493502 · ClinicalTrials.gov registry record · Phase 2
A Study of LY3041658 in Adults With Hidradenitis Suppurativa
A Phase 2 study of Hidradenitis Suppurativa, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 72
- Enrollment target
- 20
- Study locations
NCT04493502: Completed Phase 2 study of Hidradenitis Suppurativa, sponsored by Eli Lilly and Company.
NCT04493502 is a Phase 2 study of Hidradenitis Suppurativa that has completed, run by Eli Lilly and Company. The registered enrollment target is 72 participants, below the 597-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (88% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04493502, a Phase 2 study of Hidradenitis Suppurativa, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 72 participants
- Enrollment target
- 20
- Study locations
Study Summary
The reason for this study is to see if the study drug LY3041658 is effective in participants with moderate-to-severe hidradenitis suppurativa (HS).
Primary Outcome
The HiSCR is defined as at least a 50% reduction in the total abscess and inflammatory nodule count (sum of abscesses and inflammatory nodules \[AN count\]) with no increase in abscess count (A count) and no increase in draining fistulae count (DF count) relative to baseline. Non-responder imputation (NRI): Participants with missing data were considered non-responders.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG LY3041658
Study Locations (20)
Florida
- Skin Care Research, Inc - Hollywood
- Nova Clinical Research, LLC - Miami
- ForCare Clinical Research - Tampa
California
- First OC Dermatology - Fountain Valley
- Dermatology Research Associates - Los Angeles
Georgia
- Marietta Dermatology Clinical Research - Marietta
- Advanced Medical Research - Sandy Springs
Massachusetts
- Allcutis Research, Inc. - Beverly
- Beth Israel Deaconess Medical Center - Boston
Ohio
- UC Physicians Office Dermatology - Cincinnati
- University Hospitals Case Medical Center - Cleveland
Arkansas
- Northwest Arkansas Clinical Trials Center - Rogers
Missouri
- Washington University School of Medicine - St Louis
New Hampshire
- ALLCUTIS Research - Portsmouth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2020-08-26 |
| Est. Completion | 2022-10-13 |
| Phase | Phase 2 |
What the finished NCT04493502 record still lists
NCT04493502 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 72 participants, a relatively small participant target, below the 597-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Hidradenitis Suppurativa appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04493502 names 20 study sites across 14 states, led by Florida, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT04493502 about?
NCT04493502 is a clinical study titled "A Study of LY3041658 in Adults With Hidradenitis Suppurativa". The reason for this study is to see if the study drug LY3041658 is effective in participants with moderate-to-severe hidradenitis suppurativa (HS).
What is the current status of trial NCT04493502?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2020-08-26. Estimated completion is 2022-10-13.
What conditions does trial NCT04493502 study?
This clinical trial studies the following conditions: Hidradenitis Suppurativa.
What interventions are being tested in trial NCT04493502?
The interventions under investigation include: Placebo (DRUG), LY3041658 (DRUG).
Who is sponsoring clinical trial NCT04493502?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04493502 being conducted?
This trial has 20 study locations across Arkansas, California, Florida, Georgia, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hidradenitis Suppurativa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04493502's enrollment target sits among peer trials
72 30th of 52 higher than 23 of 52 other Hidradenitis Suppurativa trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hidradenitis Suppurativa trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment
RECRUITING · Phase 2
-
A Study for Evaluating Safety & Efficacy of Topical Roflumilast 0.3% Foam in Hidradenitis Suppurativa
RECRUITING · Phase 2
-
A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 2
-
A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.
RECRUITING · Phase 2
-
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
RECRUITING · Phase 2
-
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02359253 · 72 participants · NA
Robot Aided Rehabilitation - Intervention
- NCT02962661 · 72 participants · Phase 1
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
- NCT03113643 · 72 participants · Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03187535 · 72 participants · NA
Effect of TEAS on PONV After Spinal Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI